SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Q3 2024 vs. Q2 2024
How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 11 | 9 | −2 |
| Shares | 1.10M | 620.5K | −478.6K (−43.5%) |
| Value | $52.1K | $22.3K | −$29.8K (−57.1%) |
New holders (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HB Wealth Management, LLC | 310,000 | $11.2K | 0.00% |
| Clear Street LLC | 200 | $7 | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| LMR Partners LLP | 539,588 | $25.6K |
| Shaolin Capital Management LLC | 249,143 | $11.8K |
| Bank of America Corp | 200 | $9 |
| UBS Group AG | 56 | $3 |